Circulating tregs correlate with viral load reduction in chronic HBV-treated patients with tenofovir disoproxil fumarate

Journal of Clinical Immunology

Volumn 31, Issue 3, 2011, Pages 509-520

  Trehanpati, Nirupma ^a,b   Kotillil, Shyam ^c   Hissar, Syed S ^b   Shrivastava, Shikha ^b   Khanam, Arshi ^b   Sukriti, Sukriti ^b   Mishra, Siddartha K ^b   Sarin, Shiv Kumar ^a,b  

^a INSTITUTE OF LIVER AND BILIARY SCIENCES   (India)

^b G B PANT HOSPITAL   (India)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

chronicity; Hepatitis B; PBMCs; PD 1; Tregs

Indexed keywords

CHEMOKINE RECEPTOR; HEPATITIS B CORE ANTIGEN; HEPATITIS B SURFACE ANTIGEN; INTERFERON; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; TENOFOVIR DISOPROXIL; TOLL LIKE RECEPTOR; VIRUS DNA;

ADULT; ARTICLE; CD4+ CD25+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IN VIVO STUDY; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; TREATMENT DURATION; TREATMENT OUTCOME; VIRUS LOAD; VIRUS REPLICATION;

ADENINE; ADULT; ANTIGENS, CD; CASE-CONTROL STUDIES; CD8-POSITIVE T-LYMPHOCYTES; DNA, VIRAL; FEMALE; FLOW CYTOMETRY; HEPATITIS B CORE ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; IMMUNOASSAY; MALE; MIDDLE AGED; PHOSPHONIC ACIDS; PROGRAMMED CELL DEATH 1 RECEPTOR; T-LYMPHOCYTES, REGULATORY; VIRAL LOAD;

EID: 79961133360     PISSN: 02719142     EISSN: 15732592     Source Type: Journal    
DOI: 10.1007/s10875-011-9509-7     Document Type: Article

References (56)

1. RG Gish SA Locarnini 2006 Chronic hepatitis B: current testing strategies Clin. Gastroenterol. Hepatol. 4 666 676 16765304 10.1016/j.cgh.2006.03.017 1:CAS:528:DC%2BD28XmvVylsr4%3D (Pubitemid 43825809)
2. M Kumar SK Sarin 2009 Hepatitis B virus immunotolerant patients: need to differentiate patients with or without liver diseases Gastroenterology 137 2 742 743 19563835 10.1053/j.gastro.2009.05.058
3. M Kumar R Chauhan N Gupta, et al. 2009 Spontaneous increases in alanine aminotransferase levels in asymptomatic chronic hepatitis B virus infected patients Gastroenterology 136 4 1272 1280 19208347 10.1053/j.gastro.2009.01.011 1:CAS:528:DC%2BD1MXkslWgsbY%3D
4. W Lee 1997 Hepatitis B virus infection N. Engl. J. Med. 24 1733 1745 10.1056/NEJM199712113372406 (Pubitemid 27527771)
5. HJ Yim AS Lok 2006 Natural history of chronic hepatitis B virus infection: what we knew in 1981 and what we know in 2005 Hepatology 43 S173 S181 16447285 10.1002/hep.20956 1:CAS:528:DC%2BD28XhvVSktbk%3D
6. P Marcellin O Lada T Asselah 2007 Treatment of chronic hepatitis B with the combination of pegylated interferon with lamivudine Hepatol Res 37 s1 S55 S61 17627637 10.1111/j.1872-034X.2007.00106.x 1:CAS:528:DC%2BD1cXkt1OjtLw%3D (Pubitemid 47086517)
7. EI Rigopoulou D Suri S Chokshi, et al. 2005 Lamivudine plus interleukin-12 combination therapy in chronic hepatitis B: antiviral and immunological activity Hepatology 42 1028 1036 16250037 10.1002/hep.20888 1:CAS:528:DC%2BD2MXht1amtbrP (Pubitemid 43112669)
8. MK Parvez D Sehgal SK Sarin, et al. 2006 Inhibition of hepatitis B virus DNA replicative intermediate forms by recombinant interferon-gamma World J. Gastroenterol. 12 19 3006 3014 16718779 1:CAS:528:DC%2BD28XmtVOnuro%3D (Pubitemid 43811076)
9. GV Matthews DA Cooper GJ Dore 2007 Improvements in parameters of end-stage liver disease in patients with HIV/HBV-related cirrhosis treated with tenofovir Antivir. Ther. 12 1 119 122 17503756 1:CAS:528:DC%2BD2sXjs1Gnt7k%3D (Pubitemid 46340434)
10. I Rapti E Dimou P Mitsoula SJ Hadziyannis 2007 Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B Hepatology 45 307 313 17256746 10.1002/hep.21534 1:CAS:528:DC%2BD2sXisVKgu70%3D (Pubitemid 46374587)
11. MG Peters HWH Hann P Martin, et al. 2004 Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B Gastroenterology 126 1 91 101 14699491 10.1053/j.gastro.2003.10.051 1:CAS:528:DC%2BD2cXhtFGntLo%3D (Pubitemid 38040727)
12. CH Chen JH Wang CM Lee, et al. 2006 Virological response and incidence of adefovir resistance in lamivudine-resistant patients treated with adefovir dipivoxil Antivir. Ther. 11 6 771 778 17310821 1:CAS:528:DC%2BD28XhtFKgsLjJ
13. YS Lee DJ Suh YS Lim SW Jung, et al. 2006 Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy Hepatology 43 6 1385 1391 16729316 10.1002/hep.21189 1:CAS:528:DC%2BD28XmsF2msr8%3D (Pubitemid 43980117)
14. YF Liaw CM Lee RN Chien, et al. 2006 Switching to adefovir monotherapy after emergence of lamivudine-resistant mutations in patients with liver cirrhosis J. Viral Hepat. 13 4 250 255 16611191 10.1111/j.1365-2893.2005.00687.x
15. C Stephan B Dauer P Khaykin, et al. 2009 Quadruple nucleos[t]ide reverse transcriptase inhibitors- only regimen of tenofovir plus zidovudine/lamivudine/ abacavir in heavily pre-treated HIV-1 infected patients: salvage therapy or backbone only? Curr. HIV Res. 7 3 320 326 19442129 10.2174/157016209788348010 1:CAS:528:DC%2BD1MXotlWrtr4%3D
16. C Boni A Penna GS Ogg, et al. 2001 Lamivudine treatment can overcome cytotoxic T-cell hyporesponsiveness in chronic hepatitis B: new perspectives for immune therapy Hepatology 33 963 971 11283861 10.1053/jhep.2001.23045 1:CAS:528:DC%2BD3MXivVGqsLk%3D (Pubitemid 32246646)
17. Naumov NV, Cooksley H, Hou J et al. Impact of nucleoside treatment on antiviral T-cell reactivity in CHB: major differences depending on early viral suppression, HBeAg status and HBV genotype. Program and abstracts of the 57th annual meeting of the American Association for the Study of Liver Diseases; October 27-31, 2006; Boston, Massachusetts.
18. FV Chisari 2000 Rous-whipple award lecture. Viruses, immunity, and cancer: lessons from hepatitis B Am. J. Pathol. 156 1117 1132 10751335 10.1016/S0002-9440(10)64980-2 1:STN:280:DC%2BD3c3hs1Kiug%3D%3D
19. NV Naoumov S Rossol 1997 Studies of interleukin-12 in chronic hepatitis B virus infection J. Viral Hepat. 4 Suppl 2 87 91 9429215 10.1111/j.1365-2893. 1997.tb00185.x
20. VJ Cavanaugh LG Guidotti FV Chisari 1997 Interleukin-12 inhibits hepatitis B virus replication in transgenic mice J. Virol. 71 3236 3243 9060687 1:CAS:528:DyaK2sXhvVGlsrc%3D (Pubitemid 27119971)
21. R Thimme S Wieland C Steiger, et al. 2003 CD8 T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection J. Virol. 77 68 76 12477811 10.1128/JVI.77.1.68-76.2003 1:CAS:528:DC%2BD3sXkt1Sn (Pubitemid 36004947)
22. GJ Webster S Reignat D Brown, et al. 2004 Longitudinal analysis of CD8+ T cells specific for structural and nonstructural hepatitis B virus proteins in patients with chronic hepatitis B: implications for immunotherapy J. Virol. 78 5707 5719 15140968 10.1128/JVI.78.11.5707-5719.2004 1:CAS:528: DC%2BD2cXksFCgsLg%3D (Pubitemid 38661658)
23. KH Mills P McGuirk 2004 Antigen-specific regulatory T cells-their induction and role in infection Semin. Immunol. 16 2 107 117 15036234 10.1016/j.smim.2003.12.006 1:CAS:528:DC%2BD2cXht1Khtbg%3D (Pubitemid 38236182)
24. S Vigouroux E Yvon E Biagi MK Brenner 2004 Antigen-induced regulatory T cells Blood 104 1 26 33 15026316 10.1182/blood-2004-01-0182 1:CAS:528: DC%2BD2cXlslWgsrw%3D (Pubitemid 38879832)
25. S Sakaguchi 2005 Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self Nat. Immunol. 6 4 345 352 15785760 10.1038/ni1178 1:CAS:528:DC%2BD2MXisVyitLY%3D (Pubitemid 41716771)
26. EM Shevach 2006 From vanilla to 28 flavors: multiple varieties of T regulatory cells Immunity 25 2 195 201 16920638 10.1016/j.immuni.2006.08.003 1:CAS:528:DC%2BD28XpvVCqu7k%3D (Pubitemid 44224153)
27. JA Bluestone AK Abbas 2003 Natural versus adaptive regulatory T cells Nat. Rev. Immunol. 3 3 253 257 12658273 10.1038/nri1032 1:CAS:528: DC%2BD3sXitleqtLg%3D (Pubitemid 37323210)
28. T Manigold V Racanelli 2007 T-cell regulation by CD4 regulatory T cells during hepatitis B and C virus infections: facts and controversies Lancet Infect. Dis. 7 12 804 813 18045563 10.1016/S1473-3099(07)70289-X 1:CAS:528:DC%2BD1cXkvVKrtQ%3D%3D (Pubitemid 350152043)
29. D Xu J Fu L Jin H Zhang, et al. 2006 Circulating and liver resident CD4+CD25+ regulatory T cells actively influence the antiviral immune response and disease progression in patients with hepatitis B J. Immunol. 177 739 747 16785573 1:CAS:528:DC%2BD28XlvV2nu7k%3D (Pubitemid 43939189)
30. G Peng S Li W Wu Z Sun Y Chen Z Chen 2008 Circulating CD4+ CD25+ regulatory T cells correlate with chronic hepatitis B infection Immunology 123 1 57 65 17764450 10.1111/j.1365-2567.2007.02691.x 1:CAS:528: DC%2BD1cXnsFWjsg%3D%3D (Pubitemid 350255997)
31. JN Stoop RG van der Molen EJ Kuipers, et al. 2007 Inhibition of viral replication reduces regulatory T cells and enhances the antiviral immune response in chronic hepatitis B Virology 361 141 148 17184802 10.1016/j.virol.2006.11.018 1:CAS:528:DC%2BD2sXkt1ajtrY%3D (Pubitemid 46551232)
32. SM Rushbrook SM Ward E Unitt, et al. 2005 Regulatory T cells suppress in vitro proliferation of virus-specific CD8+T cells during persistent hepatitis C virus infection J. Virol. 79 7852 7859 15919939 10.1128/JVI.79.12.7852-7859.2005 1:CAS:528:DC%2BD2MXkvFCmsbc%3D (Pubitemid 40756820)
33. G Yang A Liu Q Xie TB Guo B Wan B Zhou, et al. 2007 Association of CD4+CD25+Foxp3+ regulatory T cells with chronic activity and viral clearance in patients with hepatitis B Int. Immunol. 19 2 133 140 17182968 10.1093/intimm/dxl130 1:CAS:528:DC%2BD2sXhtVKksbs%3D (Pubitemid 46179008)
34. JN Stoop RG van der Molen CC Baan, et al. 2005 Regulatory T cells contribute to the impaired immune response in patients with chronic hepatitis B virus infection Hepatology 41 771 778 15791617 10.1002/hep.20649 1:CAS:528:DC%2BD2MXjsV2msLs%3D (Pubitemid 40462939)
35. N TrehanPati R Geffers Sukriti, et al. 2008 Gene expression signatures of peripheral CD4+T cells clearly discriminate between patients with acute and chronic hepatitis B viral infection Hepatology 49 3 781 790 10.1002/hep.22696
36. C Boni A Bertoletti A Penna, et al. 1998 Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B J. Clin. Invest. 102 5 968 975 9727065 10.1172/JCI3731 1:CAS:528:DyaK1cXlvVCqtL0%3D (Pubitemid 28419565)
37. C Boni A Penna A Bertoletti, et al. 2003 Transient restoration of anti-viral T cell responses induced by lamivudine therapy in chronic hepatitis B J. Hepatol. 39 4 595 605 12971971 10.1016/S0168-8278(03)00292-7 1:CAS:528:DC%2BD3sXntVGhsbs%3D (Pubitemid 37204661)
38. YF Liaw JJY Sung WC Chow, et al. 2004 Lamivudine for patients with chronic hepatitis B and advanced liver disease N. Engl. J. Med. 351 1521 15470215 10.1056/NEJMoa033364 1:CAS:528:DC%2BD2cXot1Kls7w%3D (Pubitemid 39315319)
39. DL Barber EJ Wherry D Masopust, et al. 2006 Restoring function in exhausted CD8 T cells during chronic viral infection Nature 439 682 687 16382236 10.1038/nature04444 1:CAS:528:DC%2BD28XhtFyktL0%3D (Pubitemid 43237609)
40. DL Barber EJ Wherry D Masopust, et al. 2006 PD-1 expression on HIV specific T cells is associated with T cell exhaustion and disease progression Nature 443 350 354 10.1038/nature05115 (Pubitemid 44435155)
41. XP Nan Y Zhang HT Yu, et al. 2010 Circulating CD4+CD25high regulatory T cells and expression of PD-1 and BTLA on CD4+ T cells in patients with chronic hepatitis B virus infection Viral Immunol. 23 1 63 70 20121403 10.1089/vim.2009.0061 1:CAS:528:DC%2BC3cXisFylsr4%3D
42. DY Xie BL Lin FJ Chen H Deng, et al. 2010 Programmed death-1 (PD-1) and PD-L1 expression during antiviral treatment of chronic hepatitis B Zhonghua Gan Zang Bing Za Zhi 18 9 646 650 10.3760/cma.j.issn.1007-3418.2010.09.002 20943073 1:CAS:528:DC%2BC3MXos1Ghug%3D%3D
43. AD Frazier CL Zhang L Ni, et al. 2010 Programmed death-1 affects suppressor of cytokine signaling-1 expression in T cells during hepatitis C infection Viral Immunol. 23 5 487 495 20883163 10.1089/vim.2010.0010 1:CAS:528:DC%2BC3cXht1aktbbK
44. J Lee WI Suh EC Shin 2010 T-cell dysfunction and inhibitory receptors in hepatitis C virus infection Immune Netw 10 4 120 125 20844736 10.4110/in.2010.10.4.120
45. M Isogawa MD Robek Y Furuichi, et al. 2005 Toll-like receptor signaling inhibits hepatitis B virus replication in vivo J Virology 79 7269 7272 15890966 10.1128/JVI.79.11.7269-7272.2005 1:CAS:528:DC%2BD2MXksFKgtr0%3D (Pubitemid 40677357)
46. GJ Dore 2004 Triple infection with HIV and hepatitis B and C viruses-lesson in combination therapy AIDS 14 7 392 (Pubitemid 38943855)
47. F van Bommel T Wunsche S Mauss, et al. 2004 Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection Hepatology 40 1421 1425 15565615 10.1002/hep.20464 (Pubitemid 39657017)
48. SW Tsang HL Chan NW Leung, et al. 2001 Lamivudine treatment for fulminant hepatic failure due to acute exacerbation of chronic hepatitis B infection Aliment. Pharmacol. Ther. 15 1737 1744 11683687 10.1046/j.1365-2036.2001.01107.x 1:CAS:528:DC%2BD3MXosVWqt7s%3D (Pubitemid 33001137)
49. C Dunn D Peppa P Khanna, et al. 2009 Temporal analysis of early immune responses in patients with acute hepatitis B viral Infection Gastroenterology 137 4 1289 1300 19591831 10.1053/j.gastro.2009.06.054 1:CAS:528: DC%2BD1MXht12gtr%2FJ
50. A Das M Hoare N Davies, et al. 2008 Functional skewing of the global CD8T cell population in chronic hepatitis B virus infection J. Exp. Med. 205 9 2111 2124 18695005 10.1084/jem.20072076 1:CAS:528:DC%2BD1cXhtV2is7%2FN
51. LM Wolters BE Hansen HG Niesters, et al. 2002 Viral dynamics in chronic hepatitis B patients during lamivudine therapy Liver 22 2 121 126 12028405 10.1034/j.1600-0676.2002.01579.x 1:CAS:528:DC%2BD38Xlt1Kisr0%3D (Pubitemid 34591252)
52. P Marcellin EJ Heathcote M Buti, et al. 2008 Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B NEJM 359 23 2442 2455 19052126 10.1056/NEJMoa0802878 1:CAS:528:DC%2BD1cXhsVCrurjL
53. + regulatory T cells correlate with chronic hepatitis B infection Immunology 123 1 57 65 17764450 10.1111/j.1365-2567.2007.02691.x 1:CAS:528:DC%2BD1cXnsFWjsg%3D%3D (Pubitemid 350255997)
54. CY Lin MC Tsai CT Huang, et al. 2007 Liver injury is associated with enhanced regulatory T-cell activity in patients with chronic hepatitis B J. Viral Hepat. 14 7 503 511 17576392 10.1111/j.1365-2893.2006.00835.x (Pubitemid 46944473)
55. CK Lee JH Suh YS Cho, et al. 2002 Chemokine receptor expression of hepatitis B virus-specific CD8+ lymphocyte in chronic B viral infection Taehan Kan Hakhoe Chi 8 4 363 370 12506240
56. RM Strieter TJ Standiford GB Huffnagle, et al. 1996 "The good, the bad, and the ugly". The role of chemokines in models of human disease J. Immunol. 156 3583 3586 8621890 1:CAS:528:DyaK28XivVanurs%3D (Pubitemid 26137642)